Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Tackling Ableism After Critical Illness Is Overdue.
See All 2 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tackling Ableism After Critical Illness Is Overdue.
Hauschildt KE, Muehlschlegel S. Tackling Ableism After Critical Illness Is Overdue. Crit Care Med. 2025 Feb 26.
View in:
PubMed
authors with profiles
Susanne Muehlschlegel MD, MPH